MS Society calls out Biogen, Alkermes on Vumerity price

The National Multiple Sclerosis Society is once again standing up to companies for their pricing of new drugs. This time, the group has called out the price of Biogen and Alkermes’ newly launched Vumerity and asked the companies to refrain from excessive price hikes. Biogen said it would work with payers to tie drug costs to patient outcomes.

Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) set the wholesale acquisition cost (WAC) of Vumerity diroximel fumarate to treat relapsing-remitting MS (RRMS) at $88,000 annually, just below that of other disease-modifying therapies for MS, after announcing its approval late last month. ...